The appointment of Richard Pazdur as the new head of the FDA’s Center for Drug Evaluation and Research (CDER) follows the unexpected dismissal of George Tidmarsh, a move that has been interpreted as a strategic shift within the agency. Pazdur, who has a longstanding reputation in oncology regulation, is expected to bring stability and a renewed focus on cancer therapies, which have been a significant area of concern for the FDA.
This leadership change comes at a critical time for the FDA, as the agency faces increasing scrutiny over its approval processes and the speed at which it evaluates new drugs. Industry analysts suggest that Pazdur’s appointment may help to alleviate some of the uncertainties that have plagued the agency in recent months, potentially restoring confidence among stakeholders in the regulatory framework governing drug approvals.
Use the database as your supply chain compass →
